Blood

Vol. 146, Issue Supplement 1 Issue Supplement 1 2025
8248
Articles

Articles in this Issue

Leveraging clonal competition between chip and malignant clones as a novel therapeutic strategy in hematologic malignancy

Kiana Guillermo, Angela Fleischman Nov 03, 2025 pp. 3166-3166 10.1182/blood-2025-3166

Abstract Hematopoiesis is a polyclonal process in which hematopoietic stem cells (HSCs) are in constant competition within the bone marrow n...

Demographic and clinical risk factors for renal complications and associated non-relapse mortality in hematopoietic stem cell transplantation

Sao-Chih Ni, Ping-Chi Tsai, CHI-TING SU et al. Nov 03, 2025 pp. 7783-7783 10.1182/blood-2025-7783

Abstract Background Acute kidney injury (AKI) and chronic kidney disease (CKD) are common complications following alloge...

Real-world safety and mortality outcomes of CAR-T cell therapies versus bispecific antibodies in DLBCL: Insights from the faers database

Fatma Temiz, Işık Atagündüz, Tayfur Toptaş Nov 03, 2025 pp. 4504-4504 10.1182/blood-2025-4504

Abstract Introduction: Relapsed or refractory diffuse large b-cell lymphoma (R/R DLBCL) is associated with poor prognosis. Novel treatment m...

Infections in patients with relapsed refractory multiple myeloma receiving idecabtagene vicleucel therapy: A real-world analysis from CIBMTR

Muhammad Bilal Abid, Kitsada Wudhikarn, Qiran Ye et al. Nov 03, 2025 pp. 716-716 10.1182/blood-2025-716

Abstract Background: Infections account for over half of the non-relapse deaths among chimeric antigen receptor (CAR) T-cell recipients. Non...

Efficacy and safety of CAV (cladribine, cytarabine and venetoclax) regimen in patients with newly diagnosed Acute Myeloid Leukemia

Jinghua Liu, Jianfang Wang, Minyan Li et al. Nov 03, 2025 pp. 6955-6955 10.1182/blood-2025-6955

Abstract To explore the efficacy and safety of CAV regimen in newly diagnosed acute myeloid leukemia (AML). This study was registered in the...

DNA methylation variability in pediatric aplastic anemia contributes to T cell differentiation

Junchen Lai, Fangli Chen, Miao Yan et al. Nov 03, 2025 pp. 1417-1417 10.1182/blood-2025-1417

Abstract Aplastic anemia (AA) is caused by immune-mediated bone marrow failure and exhibits an inexplicable peak of age distribution in chil...

Trends and disparities in nutritional anemia-related mortality in the elderly in theunited states from 1999 to 2023: A CDC wonder database analysis

Muhammad Ali, Anas nasir, Ahmed Raza et al. Nov 03, 2025 pp. 7994-7994 10.1182/blood-2025-7994

Abstract Introduction: Nutritional anemia represents a common and significant public health challenge in the elderly. Nutritional anemia inc...

The ABC-14 regimen (Azacitidine, Venetoclax, and Chidamide) as a bridge to allogeneic hematopoietic stem cell transplantation for Acute Myeloid Leukemia: A single-center experience

Xiaomei Chen, Chengwei Luo, Lisi Huang et al. Nov 03, 2025 pp. 5991-5991 10.1182/blood-2025-5991

Abstract Background: The combination of azacitidine, venetoclax, and chidamide (ABC-14 regimen) has demonstrated efficacy comparable to “3+7...

First evaluation of novel cmoep (Liposomal Mitoxantrone-Based Chemotherapy) in front-line peripheral T-cell lymphoma: The compass Phase II study

Jingwei Yu, Jiesong Wang, Hongwei Xue et al. Nov 03, 2025 pp. 3647-3647 10.1182/blood-2025-3647

Abstract Background: Peripheral T-cell lymphoma (PTCL) is a heterogeneous and aggressive group of lymphoma, accounting for 25%~30% of non-Hod...

Thrombotic and hemorrhagic events and their impact on mortality among adults with newly diagnosed acute myeloid leukemia

Diego Adrianzen Herrera, Andrew Sparks, Radhika Gangaraju et al. Nov 03, 2025 pp. 2682-2682 10.1182/blood-2025-2682

Abstract Introduction Patients with acute myeloid leukemia (AML) are at increased risk of both thrombosis and bleeding a...

Impact of the CAR-T era on survival in diffuse large B-cell lymphoma: A u.S. population-based cohort study

Nishanth Thalambedu, Muthu Kumaran, Mamatha Gaddam et al. Nov 03, 2025 pp. 6334-6334 10.1182/blood-2025-6334

Abstract Background: Historically Diffuse large B-cell lymphoma (DLBCL) had poor long term survival especially in relaps...

Utilizing the complete blood count (CBC) and blood smear analysis to improve pediatric residents' skills and knowledge in hematology

David Gass, Chad McCall, Michelle Wallander et al. Nov 03, 2025 pp. 8214-8214 10.1182/blood-2025-8214

Abstract Background: Effective learning in medical education often integrates knowledge with clinical activities, particularly through hands...

Pegcetacoplan for patients with transplant-associated thrombotic microangiopathy treatment: A real-world report of six cases

Sondas Al-Sharidah, Ahmed Elhussain Nov 03, 2025 pp. 4886-4886 10.1182/blood-2025-4886

Abstract Background: Transplant-associated thrombotic microangiopathy (TA-TMA) is a severe, life-threatening complication of hematopoietic s...

Cytotoxic lymphoma assessment response (CLyAR): A harmonized, compartment-based consensus response assessment framework for cytotoxic T-cell lymphomas

Swami Iyer, Pamela Allen, Michael Khodadoust et al. Nov 03, 2025 pp. 1872-1872 10.1182/blood-2025-1872

Abstract Background: Cytotoxic T-cell lymphomas (CTLs) are rare, comprising only 3–5% of all Mature T-cell lymphomas and have very poor outc...

Integrating clinical features, long-term Outcomes and NGS-based mutational analysis in AYA patients with essential Thrombocythemia and polycythemia vera: A Multicenter Retrosepective study

Xiaojing Bao, Tian Zeng, Zhikang Zheng et al. Nov 03, 2025 pp. 7352-7352 10.1182/blood-2025-7352

Abstract Introduction: Essential thrombocythemia (ET) and polycythemia vera (PV) are myeloproliferative neoplasms (MPN)...

Final results of a first-in-human Phase I study of INA03, a novel CD71/TfR1-targeted antibody-drug conjugate, in patients with relapsed or refractory acute leukemia.

Sylvain Garciaz, Pierre Bories, Jean-Marie Boher et al. Nov 03, 2025 pp. 5203-5203 10.1182/blood-2025-5203

Abstract Background: CD71/TfR1 (transferrin receptor 1) is highly expressed in proliferative malignancies, including acute leukemias, and is...

Quantifying hemolytic response in sickle cell disease blood to mechanical and hypoxic stressors

Rucha Natu, Ojas Potdar, Umut Gurkan Nov 03, 2025 pp. 6482-6482 10.1182/blood-2025-6482

Abstract Introduction Sickle cell disease (SCD) leads to ongoing destruction of red blood cells (RBCs) within blood vessels, driven by the f...

A Phase 2, multicenter, open-label, single-arm study assessing a 4-weekly dosing schedule for mogamulizumab in patients with mycosis fungoides/Sézary syndrome (MOGA-2MG-Q4W)

Julia Scarisbrick, Christiane Querfeld, Oleg Akilov et al. Nov 03, 2025 pp. 1875-1875 10.1182/blood-2025-1875

Abstract Introduction Mogamulizumab (moga), a monoclonal antibody targeting chemokine receptor 4 (CCR4), is approved for relapsed/refractory...

Diagnostic and therapeutic patterns in cutaneous T-cell lymphomas (CTCL): Real-world data from the lymphoma epidemiology outcome-molecular epidemiology resource (LEO-MER) prospective cohort study.

Muhammad Saad Hamid, Ashley McCook-Veal, Jeffrey Switchenko et al. Nov 03, 2025 pp. 1870-1870 10.1182/blood-2025-1870

Abstract Introduction: CTCLs are rare, heterogeneous non-Hodgkin lymphomas (NHL) with significant regional variability in treatment patterns...

Transformer neural network using DNA methylation for sensitive and specific diagnosis of acute leukemia

Pedro V. B. Orsini, Francisco Marchi, Anna Lux et al. Nov 03, 2025 pp. 118-118 10.1182/blood-2025-118

Abstract Introduction The 2022 WHO Classification of Pediatric Tumors marked a major step forward in molecular diagnostics. DNA-methylation...

Real world population-based outcome analysis of small lymphocytic lymphoma (SLL) in British Columbia (BC)

Solomon Abate, Steven Huang, Elysha Vanderveer et al. Nov 03, 2025 pp. 2748-2748 10.1182/blood-2025-2748

Abstract Background: Small lymphocytic lymphoma (SLL) primarily involves lymph nodes (LNs) and is considered biologically identical to its p...

Geographic, demographic, and risk factor burden of multiple myeloma in the United States: Insights from the global burden of disease study 2021

Sameer Kumar Majety, Niyaz Shaik, Rithish Nimmagadda et al. Nov 03, 2025 pp. 5797-5797 10.1182/blood-2025-5797

Abstract Background: Multiple myeloma (MM) is a plasma cell malignancy with substantial morbidity and mortality. Understanding geographic an...

P2rx7 in AML blasts orchestrates myeloid differentiation through T cell-mediated visfatin and lymphotoxin signaling

Yunqing Liu, Hui Yuan, Hanheng Mai et al. Nov 03, 2025 pp. 5023-5023 10.1182/blood-2025-5023

Abstract Introduction:P2X7 receptor (P2RX7) overexpression has been found to be associated with a poor prognosis in human acute myeloid leuk...

A case of composite lymphoma and multiple cancer diagnoses in an individual heterozygous for FANCI variant

Heidi Christian, Ameet Kini, Fred Behm et al. Nov 03, 2025 pp. 7058-7058 10.1182/blood-2025-7058

Abstract Here we report a case of multiple malignancies in a patient with a history of superficial basal cell carcinoma (BCC) and seborrheic...

Y chromosome loss drives sex disparities in multiple myeloma by reshaping the immune landscape

Liansheng Zhang, Zuxi Feng, Lijuan Li Nov 03, 2025 pp. 7471-7471 10.1182/blood-2025-7471

Abstract Sex-based differences in cancer incidence and prognosis remain incompletely understood. Loss of the Y chromosome (LOY)-the most com...

All Issues

Journal Info

Publisher Elsevier BV
ISSN 0006-4971
E-ISSN 1528-0020
Subject Health Sciences
Language English
View Full Journal Page